DnB Asset Management
LENZ

DnB Asset Management’s LENZ Therapeutics LENZ Stock Holding History

DnB Asset Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Buy
24,993
+4,213
+20% +$34K ﹤0.01% 1250
2026
Q1 		$190K Buy
20,780
+1,617
+8% +$22.7K ﹤0.01% 1177
2025
Q4 		$307K Buy
+19,163
New +$559K ﹤0.01% 699

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

DnB Asset Management's LENZ Position: Q2 2026 in Review

DnB Asset Management increased its LENZ Therapeutics (LENZ) stake by 20% in Q2 2026, buying an estimated $34K and bringing the position to 24,993 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #1250.

DnB Asset Management first reported a position in LENZ in Q4 2025 and has held it in 3 quarters since. The position peaked at $307K in Q4 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • DnB Asset Management held 24,993 shares of LENZ Therapeutics worth $142K as of Q2 2026.
  • DnB Asset Management bought 4,213 LENZ Therapeutics shares in Q2 2026, an estimated $34K.
  • LENZ Therapeutics made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #1250 holding.
  • DnB Asset Management first reported a position in LENZ Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • DnB Asset Management's LENZ Therapeutics position peaked at $307K in Q4 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.